Company profile
Pineapple, Inc.
OTC: PNPL · Healthcare · Medical - Pharmaceuticals
#1121 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
——FH —DQ 4GM —SS 53
v0.1 · 25/100 weight · pillars only
↑ listing tenure, Piotroski F · ↓ return on assets, growth stability
Methodology →Revenue TTM
$110.6k
Rev growth YoY (TTM)
-79.5%
Net income (FY)
-$7.9M
Employees
—
as of 2026-08-28
Market cap
$51.2k
as of 2026-08-28
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$15.0k$15.0k2019
Net income-$7.9M-$7.9M2022
Operating income-$473.4k-$473.4k2022
Total assets$2.4k$2.4k2022
Liabilities$1.4M$1.4M2022
Equity-$1.4M-$1.4M2022
Revenue trend
FY2018 – FY2019 · USD
FY18
FY19
FY18
FY19
FY19
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Pineapple, Inc.’s revenue?
Pineapple, Inc. booked $15.0k in FY2019 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -52375.9% net margin.
Peers · Healthcare
REMSleep Holdings, Inc.19DGemina Laboratories Ltd.——Upper Street Marketing Inc.——Cardio Diagnostics Holdings, Inc.30DNavidea Biopharmaceuticals, Inc.——Nass Valley Gateway Ltd.——Neighbors
Los Angeles →Key facts
CEOShawn Credle
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersLos Angeles, CA
ExchangeOTC: PNPL
Employees—
IPO date1998-12-14
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.